The relationship between ceramide profile and residual inflammatory risk in patients with coronary artery disease: Insights from a prospective study.

BACKGROUND

Although progress has been made in managing cholesterol, targeting inflammation is essential for further reducing cardiovascular risk, as carvdiovascular disease (CVD) remains the leading cause of death globally. This study aimed to explore the association between plasma ceramide levels and residual inflammatory risk in patients with coronary artery disease (CAD).

METHODS

A cross-sectional observational design was adopted using data from a secondary analysis of a multicenter prospective cohort study in China. Patients were categorized into two groups based on a high-sensitivity C-reactive protein (hsCRP) level of 2.0 mg/L. Plasma ceramide (Cer) levels were measured using the LC-MS/MS system. By collecting and statistically analyzing patient demographic and clinical characteristics, differences were compared between the low residual inflammatory risk group (Low RIR) and the high residual inflammatory risk group (High RIR). Multivariate logistic regression analysis was used to assess the interaction of plasma ceramides with high residual inflammation risk.

RESULTS

A total of 778 patients with confirmed CAD were included in the study. Compared to the Low RIR, Cer (d18:1/16:0), Cer (d18:1/18:0), Cer (d18:1/20:0), Cer (d18:1/22:0), Cer (d18:1/24:0), and Cer (d18:1/24:1), were significantly elevated in the High RIR group. Spearman correlation analysis indicated that Cer (d18:1/16:0) levels were positively correlated with hsCRP. Further multivariable logistic regression analysis revealed that Cer (d18:1/16:0) was a significant independent indicator of high RIR beyond conventional cardiovascular risk factors.

CONCLUSION

This study found a significant association between a specific plasma ceramide Cer (d18:1/16:0) and high residual inflammatory risk in CAD patients, suggesting it could be an important inflammatory biomarker in the management of CVD.